News Daily News Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments Michael O'Riordan January 03, 2025
News Daily News Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced Michael O'Riordan September 20, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Daily News COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK Michael O'Riordan September 15, 2022
News Daily News Optimal Medical Therapy for Stable Angina: Which Drugs? How Long? Michael O'Riordan January 25, 2022
News Conference News EuroPCR 2021 Elective Revascularization, Better Long-term Survival: Meta-analysis Michael O'Riordan May 18, 2021
News Conference News TCT 2020 Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care Michael O'Riordan October 19, 2020
News Conference News TCT 2018 Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos Michael O'Riordan October 02, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Daily News El AAC Echa Marcha Atrás en su Postura Contra la Revascularización Completa Todd Neale October 03, 2014